Why the study?
Does the APOAV (T-1131C) polymorphism rare allele affect plasma triglyceride and lipoprotein cholesterol levels in dyslipidemic and control populations?
Does the APOAV (T-1131C) polymorphism rare allele affect plasma triglyceride and lipoprotein cholesterol levels in dyslipidemic and control populations?
The APOAV (T-1131C) polymorphism rare allele is associated with elevated plasma triglycerides and VLDL cholesterol, suggesting it is an important determinant of lipid profiles and a potential cardiovascular risk factor.
Answers are grounded in this paper and cite their sources.
Rare APOAV allele linked to adverse lipids in cross-sectional data; hypothesis-generating for CV risk, needs prospective validation.
Recent discovery and characterization of APOAV suggests a role in metabolism of triglyceride (TG)-rich lipoproteins. Previously, variation at the APOAV locus was shown to modestly influence plasma TGs in normolipidemic samples. The aims of this study were to assess the effects of a polymorphism in APOAV (T-1131C) in terms of its frequency among three dyslipidemic populations and a control population, differences of allele frequency across available ethnic groups, and associations with specific lipoprotein TG and cholesterol compartments. We found a striking elevation in the frequency of the rare allele in a Chinese population (P = 0.0002) compared with Hispanic and European populations. The rare allele of the polymorphism was associated with elevated plasma TG (P = 0.012), VLDL cholesterol (P = 0.0007), and VLDL TG (P = 0.012), LDL TG (P = 0.003), and HDL TG (P = 0.016). Linear regression models predict that possession of the rare allele elevates plasma TG by 21 mg/dl (P = 0.009) and VLDL cholesterol by 8 mg/dl (P = 0.0001), and reduces HDL cholesterol by 2 mg/dl (P = 0.017). The association of the polymorphism with altered lipoprotein profiles was observed in combined hyperlipidemia, hypoalphalipoproteinemia, and hyperalphalipoproteinemia, and in controls. These findings indicate that APOAV is an important determinant of plasma TG and lipoprotein cholesterol, and is potentially a risk factor for cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Aouizerat et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: